课题基金 / 基金详情

项目摘要

项目成果

CHYI S HSIEH的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The gastrointestinal (GI) tract is a large surface lined by a single layer epithelium which is exposed to trillions of microbes and innocuous substances from the diet. The largest collection of immune cells in the body underlies this single layer epithelium and monitors the luminal contents to maintain tolerance to dietary and commensal antigens in the steady-state while retaining the ability to rapidly induce immunity to pathogens during infection. While great progress has been made in elucidating the role(s) of specific immune cell subsets, cytokines, and other factors promoting tolerance or immunity, the processes intrinsic to the gut that enable the immune system to switch from an overwhelmingly tolerogenic tone in the steady-state to inflammatory responses during infection remains a gap in our understanding. Recently, we have uncovered that inhibiting goblet cell associated antigen passages (GAPs) in the small intestine (SI) rapidly shifts the immunologic tone away from tolerance and promotes the rapid induction of inflammatory Th17 responses in the absence of infection or injury. We hypothesize that the inhibition of GAPs is a physiologic response to enteric infection, which in and of itself, promotes the generation of Th17 cells and inflammatory cytokines and shifts the tone of the immune system away from tolerance toward immunity. By studying this process in the absence of enteric infection or injury we can disentangle contributions of the pathogen and injury to the inflammatory response from intrinsic properties of the gut ecosystem promoting the switch from a tolerogenic to pro-inflammatory state. Understanding intrinsic properties of the gut that allows the rapid generation of protective responses could provide new approaches to treat enteric infections and provide insight into the pathogenesis of chronic inflammatory diseases of the gut. We hypothesize that when SI GAPs are inhibited, other pathways take over driving the development and/or expansion of Th17 cells specific for dietary, microbial, and/or self antigens, which shifts the tone of the immune system to provide enhanced protection during enteric infection and/or injury. To explore this hypothesis we propose the following specific aims: In aim 1 we will identify the early events resulting in Th17 expansion following SI GAP inhibition, in aim 2 we will define the origins and specificities of the Th17 cells that expand when SI GAPs are inhibited in aim 3 we will determine if the inhibition of SI GAPs is protective in models of enteric infection and whether inappropriate inhibition of SI GAPs potentiates intestinal inflammatory disease.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1080/19490976.2021.2007743
发表时间: 2022-01
期刊: Gut microbes
影响因子: 12.2
作者: [Udayan S, Stamou P, Crispie F, Hickey A, Floyd AN, Hsieh CS, Cotter PD, O'Sullivan O, Melgar S, O'Toole PW, Newberry RD, Rossini V, Nally K]
通讯作者: Nally K
Small Intestinal Goblet Cells Control Humoral Immune Responses and Mobilization During Enteric Infection.
小肠杯状细胞控制肠道感染期间的体液免疫反应和动员。
DOI: 10.1101/2024.01.06.573891
发表时间: 2024
期刊: bioRxiv : the preprint server for biology
影响因子: --
作者: [Kulkarni,DeveshaH, Talati,Khushi, Joyce,ElisabethL, Kousik,Hrishi, Harris,DaliaL, Floyd,AlexandriaN, Vavrinyuk,Vitaly, Barrios,Bibianna, Udayan,Sreeram, McDonald,Keely, John,Vini, Hsieh,Chyi-Song, Newberry,RodneyD]
通讯作者: Newberry,RodneyD
CAR-T cell treatment of CNS Autoimmunity
  • 批准号:
    10641913
  • 项目类别:
  • 资助金额:
    $68.34万
  • 财政年份:
    2022
  • 负责人:
    CHYI S HSIEH
  • 依托单位:
CAR-T cell treatment of CNS Autoimmunity
  • 批准号:
    10539779
  • 项目类别:
  • 资助金额:
    $67.19万
  • 财政年份:
    2022
  • 负责人:
    CHYI S HSIEH
  • 依托单位:
B cell-targeted CAR-T treatment of CNS Autoimmunity
  • 批准号:
    10514950
  • 项目类别:
  • 资助金额:
    $23.63万
  • 财政年份:
    2022
  • 负责人:
    CHYI S HSIEH
  • 依托单位:
Immune interactions with commensal microbes in early life
  • 批准号:
    10567936
  • 项目类别:
  • 资助金额:
    $71.52万
  • 财政年份:
    2022
  • 负责人:
    CHYI S HSIEH
  • 依托单位:
海外基金